CORT GoodMoat Verdict
Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.
Corcept Therapeutics Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym ®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California.
Did you know?
Generated $672.0 in free cash flow for every $1 of capital expenditure in FY25.
Current Price
$51.42
+10.53%GoodMoat Value
$16.61
67.7% overvaluedProfile
Valuation (TTM)
Market Cap$5.47B
P/E117.20
EV—
P/B8.44
Shares Out106.37M
P/Sales7.11
Revenue$769.10M
EV/EBITDA—
Corcept Therapeutics Inc (CORT) Quality Analysis
CORT Profitability
Profitability trend analysis coming soon
CORT Growth
Growth trend analysis coming soon
CORT Financial Health
Financial health indicators coming soon
CORT Quality & Fundamental Analysis
Corcept Therapeutics Inc (CORT) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. This quality analysis page evaluates Corcept Therapeutics Inc's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
Corcept Therapeutics Inc has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of 6.07% and a return on equity (ROE) of 7.20%. Return on assets (ROA) stands at 5.58%.
The debt-to-equity ratio is 0.01, with a current ratio of 2.92. Operating margin is 5.88%.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether Corcept Therapeutics Inc is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.